Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by XTX Topco Ltd

XTX Topco Ltd reduced its stake in shares of Veracyte, Inc. (NASDAQ:VCYT) by 56.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,223 shares of the biotechnology company’s stock after selling 26,970 shares during the quarter. XTX Topco Ltd’s holdings in Veracyte were worth $840,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of VCYT. Vanguard Group Inc. increased its holdings in Veracyte by 6.0% during the 4th quarter. Vanguard Group Inc. now owns 8,211,612 shares of the biotechnology company’s stock valued at $325,180,000 after acquiring an additional 463,098 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in Veracyte by 31.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 6,599,264 shares of the biotechnology company’s stock valued at $261,331,000 after buying an additional 1,576,432 shares in the last quarter. Geode Capital Management LLC grew its holdings in Veracyte by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,844,713 shares of the biotechnology company’s stock valued at $62,806,000 after buying an additional 17,921 shares during the last quarter. Jennison Associates LLC increased its position in Veracyte by 116.3% during the fourth quarter. Jennison Associates LLC now owns 833,754 shares of the biotechnology company’s stock worth $33,017,000 after buying an additional 448,251 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in Veracyte by 0.4% during the fourth quarter. New York State Common Retirement Fund now owns 785,971 shares of the biotechnology company’s stock worth $31,124,000 after buying an additional 3,111 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VCYT. StockNews.com downgraded Veracyte from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Guggenheim decreased their price target on shares of Veracyte from $45.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. UBS Group boosted their price objective on shares of Veracyte from $46.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Stephens reissued an “overweight” rating and set a $45.00 price objective on shares of Veracyte in a research note on Wednesday, March 26th. Finally, Craig Hallum started coverage on shares of Veracyte in a research note on Thursday, March 20th. They issued a “buy” rating and a $45.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Veracyte presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Veracyte Price Performance

Shares of NASDAQ:VCYT opened at $31.53 on Thursday. The business has a 50-day moving average of $33.56 and a two-hundred day moving average of $37.38. The firm has a market capitalization of $2.46 billion, a PE ratio of -210.20 and a beta of 2.03. Veracyte, Inc. has a 12 month low of $18.61 and a 12 month high of $47.32.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The firm had revenue of $118.63 million for the quarter, compared to analysts’ expectations of $110.73 million. During the same period in the previous year, the company posted ($0.39) earnings per share. As a group, research analysts anticipate that Veracyte, Inc. will post 0.68 earnings per share for the current year.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.